Penumbra Inc
$ 318.01
-0.10%
20 Jul - close price
- Market Cap 12,519,979,000 USD
- Current Price $ 318.01
- High / Low $ 318.75 / 317.63
- Stock P/E 73.52
- Book Value 37.48
- EPS 4.33
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.13 %
- 52 Week High 362.41
- 52 Week Low 221.26
About
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
Analyst Target Price
$362.54
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-07-29 | 2025-04-23 | 2025-02-18 | 2024-10-30 | 2024-07-30 | 2024-05-07 | 2024-02-22 | 2023-11-02 | 2023-08-01 |
| Reported EPS | 0.82 | 1.18 | 0.97 | 0.86 | 0.83 | 0.97 | 0.85 | 0.64 | 0.41 | 0.76 | 0.67 | 0.43 |
| Estimated EPS | 1.08 | 1.1 | 0.9 | 0.82 | 0.67 | 0.8937 | 0.69 | 0.56 | 0.38 | 0.7 | 0.45 | 0.28 |
| Surprise | -0.26 | 0.08 | 0.07 | 0.04 | 0.16 | 0.0763 | 0.16 | 0.08 | 0.03 | 0.06 | 0.22 | 0.15 |
| Surprise Percentage | -24.0741% | 7.2727% | 7.7778% | 4.878% | 23.8806% | 8.5375% | 23.1884% | 14.2857% | 7.8947% | 8.5714% | 48.8889% | 53.5714% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PEN
2026-07-17 15:10:50
Morningstar analyst Debbie S. Wang reiterated that the risk of antitrust challenges for Boston Scientific's planned acquisition of Penumbra remains low. The article highlights Penumbra's history of creating innovative endovascular devices for blood clots and aneurysms, positioning it as a growing competitor to larger players like Stryker and Medtronic. The acquisition is expected to close by the end of 2026.
2026-07-15 09:41:18
This article provides a forum and discussion board for Penumbra (PEN) stock. It allows investors to share insights and engage in discussions about the company's performance, news, and future outlook. The content is primarily user-generated, focusing on various aspects relevant to PEN shareholders and potential investors.
2026-07-13 10:10:12
This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying neutral near and mid-term readings but a positive long-term bias. It outlines distinct institutional trading strategies, including position, momentum breakout, and risk hedging, tailored to different risk profiles. The analysis also provides multi-timeframe signal insights, highlighting support and resistance levels for PEN.
2026-07-11 06:10:17
This article provides the enterprise value to EBITDA forward for Penumbra, Inc. (NYSE: PEN). It indicates that the market was closed and no trades occurred at the time of publication, with data provided by ICE Data Services and FactSet.
2026-07-08 15:40:29
Penumbra has initiated a clinical trial to evaluate its RED reperfusion catheter portfolio for mechanical thrombectomy in patients with M2 occlusions, a subset of acute ischemic stroke. This study aims to inform treatment selection and potentially broaden the adoption of mechanical thrombectomy for this challenging condition, especially after previous studies suggested no benefit of endovascular treatment for such blockages. The trial will enroll up to 250 patients across approximately 40 sites, with some receiving medical management alongside Penumbra's devices, including the recently authorized Thunderbolt system.
2026-07-07 20:17:43
Penumbra, Inc. has initiated its FORWARD study, an international, multi-center study to evaluate the safety and efficacy of mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT™), for distal acute ischemic stroke. The study, which has enrolled its first patient, aims to determine if these advanced treatments can improve outcomes for patients with distal occlusions, a challenging stroke subtype. Distal occlusions account for a significant portion of acute ischemic strokes, and the FORWARD study will assess Penumbra's RED reperfusion catheter portfolio, including the THUNDERBOLT CAVT platform.
